Expression and distribution of glucagon-like peptide-1 receptor mRNA, protein and binding in the male nonhuman primate ( Macaca mulatta ) brain
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes In patients with preexisting cardiovascular disease and overweight or obesity but without diabetes, weekly subcutaneous semaglutide at a dose of 2.4 mg was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke at a mean follow-up of 39.8 months #AHA2023 nejm.org/doi/full/10.10 Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes In patients with preexisting cardiovascular disease and overweight or obesity but without diabetes, weekly subcutaneous semaglutide at a dose of 2.4 mg was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke at a mean follow-up of 39.8 months #AHA2023 nejm.org/doi/full/10.10 Join the conversation
Comparisons of Mounjaro (Eli Lilly), Trulicity (Eli Lilly) and Rybelsus (Novo Nordisk), respectively, also generated the most interest
In addition, participants were strongly encouraged to fast on the day of the MR scan to minimize potential effects of food intake [48, 49] (one individual with ASD could not follow the instruction and had a light meal)
